Inventor · disambiguated record
Milan Bruncko
Also filed as: BRUNCKO MILAN
44 granted patents·41 pending applications·1,442 citations·filing 1998–2024
98Inventor score
Top patents by PatentIndex Score
85 records- 0198US8546399B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesBRUNCKO MILAN·Filed 2010·Granted Oct 1, 2013·100 cites·24 claims
- 0298US7973161B2Apoptosis promotersABBOTT LAB·Filed 2006·Granted Jul 5, 2011·70 cites·5 claims
- 0398US7767684B2Apoptosis promotersABBOTT LAB·Filed 2005·Granted Aug 3, 2010·107 cites·7 claims
- 0498US7642260B2Apoptosis promotersABBOTT LAB·Filed 2005·Granted Jan 5, 2010·82 cites·2 claims
- 0598US7390799B2Apoptosis promotersABBOTT LAB·Filed 2006·Granted Jun 24, 2008·331 cites·12 claims
- 0698US6720338B2N-acylsulfonamide apoptosis promotersABBOTT LAB·Filed 2001·Granted Apr 13, 2004·98 cites·9 claims
- 0797US9174982B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Nov 3, 2015·38 cites·7 claims
- 0897US8686136B2Apoptosis promotersABBVIE INC·Filed 2012·Granted Apr 1, 2014·20 cites·2 claims
- 0997US8586754B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2010·Granted Nov 19, 2013·59 cites·8 claims
- 1097US8563735B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2009·Granted Oct 22, 2013·72 cites·4 claims
- 1197US8354404B2Apoptosis promotersABBOTT LAB·Filed 2011·Granted Jan 15, 2013·39 cites·8 claims
- 1297US8173811B2Apoptosis promotersBRUNCKO MILAN·Filed 2010·Granted May 8, 2012·50 cites·4 claims
- 1397US7754886B2N-acylsulfonamide apoptosis promotersABBOTT LAB·Filed 2009·Granted Jul 13, 2010·34 cites·18 claims
- 1497US7709467B2Apoptosis promotersABBOTT LAB·Filed 2008·Granted May 4, 2010·50 cites·10 claims
- 1597US7504512B2N-acylsulfonamide apoptosis promotersABBOTT LAB·Filed 2004·Granted Mar 17, 2009·58 cites·18 claims
- 1696US8614318B2Apoptosis promotersBRUNCKO MILAN·Filed 2006·Granted Dec 24, 2013·37 cites·2 claims
- 1796US8084607B2Apoptosis promotersBRUNCKO MILAN·Filed 2009·Granted Dec 27, 2011·43 cites·5 claims
- 1896US7585858B2N-sulfonylcarboximidamide apoptosis promotersABBOTT LAB·Filed 2005·Granted Sep 8, 2009·19 cites·4 claims
- 1993US7906505B2Apoptosis promotersABBOTT LAB·Filed 2010·Granted Mar 15, 2011·18 cites·4 claims
- 2092US8940737B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Jan 27, 2015·7 cites·10 claims
- 2191US9303025B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Apr 5, 2016·11 cites·4 claims
- 2290US9072748B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jul 7, 2015·11 cites·10 claims
- 2389US11633497B2Anti-c-Met antibody drug conjugatesABBVIE INC·Filed 2022·Granted Apr 25, 2023·1 cites·8 claims
- 2489US9125913B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Sep 8, 2015·10 cites·6 claims
- 2588US8889675B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Nov 18, 2014·3 cites·9 claims
- 2687US7981888B21-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivativesABBOTT LAB·Filed 2008·Granted Jul 19, 2011·8 cites·7 claims
- 2787US2024285611A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 2886US9266877B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Feb 23, 2016·2 cites·2 claims
- 2986US9227963B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Jan 5, 2016·2 cites·2 claims
- 3086US2025019364A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2024·Application pending·0 cites
- 3183US2024043404A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 3282US11897864B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2022·Granted Feb 13, 2024·0 cites·27 claims
- 3381US2025213685A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2024·Application pending·0 cites
- 3481US2025263491A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2024·Application pending·0 cites
- 3580US8445679B27-substituted indole MCL-1 inhibitorsWANG XILU·Filed 2008·Granted May 21, 2013·7 cites·4 claims
- 3677US9877958B2Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2016·Granted Jan 30, 2018·1 cites·16 claims
- 3777US9844547B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2015·Granted Dec 19, 2017·1 cites·10 claims
- 3876US9650358B2Pyridine CDK9 kinase inhibitorsABBVIE INC·Filed 2014·Granted May 16, 2017·1 cites·18 claims
- 3976US9035047B27-substituted indole Mcl-1 inhibitorsABBVIE INC·Filed 2013·Granted May 19, 2015·1 cites·4 claims
- 4075US2022315555A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2021·Application pending·0 cites
- 4175US2021221789A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2020·Application pending·0 cites
- 4274US11786519B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2020·Granted Oct 17, 2023·0 cites·5 claims
- 4374US2024199745A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2023·Application pending·0 cites
- 4474US2021346369A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2020·Application pending·0 cites
- 4573US2020345717A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2019·Application pending·0 cites
- 4673US2020253954A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2019·Application pending·0 cites
- 4773US2023372519A1Anti-c-met antibody drug conjugatesABBVIE INC·Filed 2023·Application pending·0 cites
- 4872US9359296B27-substituted indole Mcl-1 inhibitorsABBVIE INC·Filed 2015·Granted Jun 7, 2016·1 cites·2 claims
- 4972US6504031B1Naphthamidine urokinase inhibitorsFiled 2000·Granted Jan 7, 2003·5 cites·2 claims
- 5072US2023114718A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 85 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Milan Bruncko files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →